Lecanemab and donanemab (Kisunla), another anti-amyloid treatment, won approval based on evidence that they slowed cognitive ...

Donanemab – one of the first drugs to slow down early-stage Alzheimer’s disease – will not be available on the NHS in ...

One described the approval of lecanemab as “no panacea” for patients, for example, while another went as far as to suggest that, in their eyes, donanemab offered “no net benefit” at all.

Medications like donanemab (Kisunla) and lecanemab (Leqembi) target amyloid plaques that build up in the brain due to ...

Using new, highly sensitive methods, the researchers detected and visualized how amyloid beta protein—a plaque that builds up in the brains of people with Alzheimer's disease—binds to lecanemab, ...

This groundbreaking research reveals that subtle chemical changes in tau may quietly set off a chain reaction, spreading ...

Campaigners have called for a change in the way treatments for dementia are assessed in the wake of the decision on the drug ...

Donanemab works similarly to lecanemab, another promising Alzheimer's drug. Patients on lecanemab need infusions every two weeks, while donanemab is administered once a month. Between his ...

Donanemab, made by Eli Lilly and sold under the brand name Kisunla, is not a cure, nor can it reverse memory loss, doctors say. But research has shown that, like its predecessor lecanemab ...

Overall, the clinical experience with lecanemab is consistent with trial data, Shiner concluded. Her center has just begun giving donanemab. Talya Nathan, also at the Tel Aviv Sourasky Medical Center, ...

At that level, both lecanemab and donanemab act very similarly. "Further work is needed to understand what is most important: binding oligomeric structures or binding amyloid plaques. This is ...